Management and Board of Directors
Management
Torsten Freltoft
CEO
Born 1958. CEO since 2014.
Torsten Freltoft, PhD, has a doctorate in solid state physics from the University of Copenhagen. Freltoft has broad and solid experience regarding management of companies in the biotech industry. Among other assignments, Freltoft led Sophion Bioscience A/S for 13 years, from its inception in 2000 to a turnover of approximately USD 20 million in 2013 and was also responsible for the exit that Sophion Bioscience A/S carried out together with a US investment bank in 2011. Freltoft has in addition served as CEO of PlastiSens ApS and Chemometec A/S, among others. Freltoft has also held a number of board assignments, and held scientific assignments for the EU and the Danish government. Freltoft is currently serving as a board member in the following companies: XNovo Technology ApS and PlastiSens ApS both located in Denmark.
Shareholding in AcouSort: 885,789 shares (30-06-2024).
Torsten Freltoft is not independent in relation to the Company and its executive officers, but independent to major shareholders.
Gunnar Telhammar
CFO
Born 1961. CFO as a consultant since 2016.
Gunnar Telhammar has an MBA at Lund University. Telhammar has many years of experience from executive positions in the biotech industry. Since 2005 he has been CEO of BioFinans AB and since 2013 he has worked as Interim CFO for several listed companies. In addition to his experience as CFO, he has many years of experience as a board member. Telhammar is currently serving as CFO in AcouSort AB, Xintela AB, Tendo AB, Targinta AB and ImmuneBiotech AB as well as CEO and board member in BioFinans AB.
Prior assignments the last five years are CFO in A1M Pharma AB, Preelumina Diagnostics AB, SensoDetect AB and board member in Targinta AB.
Shareholding in AcouSort: 5,560 shares (30-06-2024).
Gunnar Telhammar is not independent in relation to the Company and its executive officers, but independent to major shareholders.
Agnes Michanek
Commercial Director
Born 1981. Commercial Director since 2022.
Agnes Michanek, PhD, has a doctorate in physical chemistry from Lund University. As the Commercial Director she leads the company’s sales, marketing, business development, and application development initiatives, successfully fostering collaborations with industrial partners. With extensive experience in managing innovation projects, she has a proven track record in leading new product development projects bringing novel point-of-care diagnostic devices to the market. In addition, Michanek has experience in developing strategic processes, leading strategic marketing initiatives and managing international collaborations. Her expertise also extends to designing innovative solutions for medical devices. Her previous assignments include roles as Customer Application Manager in the Company, and project and program manager for HemoCue and Oatly.
Shareholding in AcouSort: 4,274 shares (30-06-2024).
Agnes Michanek is not independent in relation to the Company and its executive officers, but independent to major shareholders.
Magnus Hivert
Director, Product Development & Production
Born 1976. Director of Product Development & Production since 2017.
Magnus Hivert, PhD, has a doctorate in solid state physics from Lund University. Hivert is an experienced Product Development and Production Manager with a proven track record in leading innovative medical device projects from concept to commercialization. Hivert has demonstrated expertise in product development, quality management, manufacturing, and business development within the medical technology industry. Hivert has a strong technical background in nanotechnology, microfluidics, and materials science, coupled with a deep understanding of regulatory requirements and market dynamics. Hivert has proven ability to collaborate effectively with cross-functional teams, manage complex projects, and drive successful outcomes.
Shareholding in AcouSort: 2,671 shares (30-06-2024).
Magnus Hivert is not independent in relation to the Company and its executive officers, but independent to major shareholders.
Henrik Johansson
Director, Research & Technology
Born 1980. Director of Research and Technology since 2023.
Henrik Johansson, PhD, has a doctorate in genetics from Uppsala University. He joined AcouSort in 2023 and is responsible for the research activities aimed at further developing and applying the core acoustophoresis technology. Prior to joining AcouSort, he has experience from start-up environment as well as from larger companies in the biotech space. He has held management positions at Agilent and Revvity, leading multidisciplinary teams, where he has played key roles in driving early discovery of new methods to address unmet needs in the diagnostic market and in developing proprietary technologies from idea stage to profitable products.
Shareholding in AcouSort: 0 shares (30-06-2024).
Henrik Johansson is not independent in relation to the Company and its executive officers, but independent to major shareholders.
Board of Directors
Martin Olin
Chairman of the Board
Born 1969. Chairman of the Board since 2021.
Martin Olin holds a M.Sc. in Business and Auditing, MBA, Executive Board Program (CBS) and Executive Breakthrough Program (Egon Zehnder). Olin has held executive positions as CEO, CFO or Director in international Life Science companies including Novo Nordisk and Symphogen A/S and has over the years held numerous board assignments in the Nordics as well as international enterprises. He currently holds assignments as CEO of BerGenBio ASA, chairman of the board at DanGroup Alarm, board member of Cessatech A/S (publ.). Prior assignments the last five years are CEO of Nordic Eye Venture Capital, CEO and board member of Symphogen A/S.
Shareholding in AcouSort: 11,905 shares (30-06-2024).
Martin Olin is independent in relation to the Company, executive officers and major shareholders.
Thomas Laurell
Board Member
Born 1961. Board member since 2011.
Thomas Laurell, PhD, is Professor of Medical and Chemical Microsensors at Lund University and is a Fellow at the School of Engineering, Tokyo University. Laurell has been elected to the Royal Swedish Academy of Sciences since 2010, the Royal Swedish Academy of Engineering Sciences since 2007 and the Royal Physiographical Society in Lund since 2007. Professor Laurell is a world-leading researcher in acoustophoresis based on microtechnology and has contributed to the authoring of over 250 scientific articles and 33 patent applications. Professor Laurell also has a solid commercial background and has started several companies including AcouSort and has experience of board work in these. In addition to his academic and commercial experience, Professor Laurell has received a number of awards in science, innovation and entrepreneurship. The research conducted by the group led by Professor Laurell forms the basis of AcouSort’s operations.
Shareholding in AcouSort: 1,096,990 shares (30-06-2024).
Thomas Laurell is independent in relation to the Company, executive officers and major shareholders.
Stefan Scheding
Board Member
Born 1962. Board member since 2012.
Stefan Scheding, Dr. med., is Professor and Research Group Leader at the Department of Molecular Hematology and Lund’s Stem Cell Center at Lund University. Dr Scheding is also a consultant at the Department of Hematology at the Skåne University Hospital in Lund. A main focus of Dr. Scheding’s research is the development of new therapies in hematological cancers and stem cell transplants. Dr. Scheding is a member of several national and international hematology and cell therapy research councils and has contributed to over 90 scientific articles in his research areas.
Shareholding in AcouSort: 907,524 shares (30-06-2024).
Stefan Scheding is independent in relation to the Company, executive officers and major shareholders.
Katherine Flagg
Board Member
Born 1962. Board member since 2021.
Katherine Flagg has a BSc. from Douglas College/Rutgers University. Flagg provides successful experience driving new businesses, growing market share, and expanding customer base within the pharmaceutical, diagnostic and research markets. Katherine is an exceptional communicator who effectively interacts across all organizational levels, consistently delivering sales results and maximizing account loyalty while driving new technologies into the Life Science market. Katherine Flagg is Business Unit Director at Standard Bio Tools (formerly Fluidigm Corporation) and has prior assignments the last five years as SVP Americas, Gyros Protein Technology.
Shareholding in AcouSort: 0 shares (30-06-2024).
Katherine Flagg is independent in relation to the Company, executive officers and major shareholders.
